See the materials below for additional product information and patient education.
Product Fact SheetDOWNLOAD
Patient Biosimilar Education Video
UDENYCA® cost savings and expanded access
Simulation modeling of cost-savings from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced neutropenia, and budget-neutral expanded access to prophylaxis and anti-neoplastic therapy from derived cost-savings in non-Hodgkin lymphoma1
McBride A, MacDonald K, Abraham I
- "These simulation models demonstrate that significant cost savings for supportive cancer care can be generated through conversion to biosimilar pegfilgrastim-cbqv for CIN/FN prophylaxis"
- "The savings generated from conversion from PEG/PEG-OBI can be reallocated on a budget-neutral basis to provide expanded access to additional patients/cycles of CIN/FN prophylaxis with biosimilar pegfilgrastim-cbqv or to curative anti-neoplastic treatment. Such efficiency and expanded access enhance the value of cancer care to payers and patients"
This study was first presented at the 62nd ASH Annual Meeting and
Exhibition, Oral and Poster Abstracts.
CIN/FN=chemotherapy-induced (febrile) neutropenia;
PEG-OBI=Neulasta® (pegfilgrastim) on-body injector.
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv2
MacDonald K, McBride A, Alrawashdh N, Abraham I
- "Converting 20,000 patients from reference to pegfilgrastim-cbqv over 6 cycles can generate savings up to $246.7M, enough to purchase up to 58,253 additional doses of pegfilgrastim-cbqv"
- "This simulation provides economic justification for prophylaxis with biosimilar pegfilgrastim-cbqv"